Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)

BACKGROUND: Therapy of primary CNS lymphoma (PCNSL) has focused on multi-agent chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of rituximab with high-dose methotrexate (HD-MTX)-based ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Swinnen, Lode J., O’Neill, Anne, Imus, Philip H., Gujar, Sachin, Schiff, David, Kleinberg, Lawrence R., Advani, Ranjana H., Dunbar, Erin M., Moore, Dennis, Grossman, Stuart A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787508/
https://www.ncbi.nlm.nih.gov/pubmed/29416652
http://dx.doi.org/10.18632/oncotarget.22332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787508/
https://www.ncbi.nlm.nih.gov/pubmed/29416652
http://dx.doi.org/10.18632/oncotarget.22332

Ejemplares similares